POMDOCTOR LIMITED Announces ADS Ratio Change to Be Effective on June 22, 2026
Rhea-AI Summary
POMDOCTOR (NASDAQ:POM) will change its ADS-to-Class A ordinary share ratio effective June 22, 2026 (U.S. Eastern Time). The ratio will move from 1 ADS representing 1/6 share to 1 ADS representing 3 shares, equivalent to a one-for-eighteen reverse ADS split.
ADSs in DRS and DTC will be automatically exchanged, with 18 existing ADSs consolidated into 1 new ADS. No fractional ADSs will be issued; the depositary will sell aggregated fractions and distribute net cash. The ADSs will keep ticker POM and adopt new CUSIP 73181R207.
Positive
- One-for-eighteen reverse ADS split expected to proportionally increase ADS trading price
- ADS ratio change and exchange process will occur automatically for DRS and DTC holders
- ADSs will continue trading on Nasdaq under the same ticker symbol POM
Negative
- Every eighteen existing ADSs will be consolidated into one new ADS, reducing ADS count
- No fractional ADSs issued; fractional positions will be sold with only net cash proceeds paid
News Market Reaction – POM
In the Jun 17 session, POM declined 3.97%, reflecting a moderate negative market reaction. Argus tracked a peak move of +8.5% during that session. Argus tracked a trough of -14.6% from its starting point during tracking. Our momentum scanner triggered 11 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 28 | ADS ratio plan | Negative | -8.2% | Announced plan for 1-for-18 reverse ADS split via ratio change. |
| May 14 | Earnings results | Negative | -3.3% | Reported FY 2025 revenue growth alongside a sharply wider net loss. |
| Mar 13 | AI strategy update | Positive | +3.3% | Announced AI plus smart wearables focus for chronic disease ecosystem. |
| Feb 04 | Platform expansion | Positive | -1.5% | Expanded integration with online medical insurance across major cities. |
| Feb 02 | Nasdaq notice | Negative | +5.2% | Received Nasdaq deficiency letter for bid price under $1.00 requirement. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
News flow has often been followed by weakness, including the prior ADS ratio plan and earnings, while selected strategic or compliance updates have drawn mixed reactions.
Over the last few months, POMDOCTOR progressed from platform expansion news on Feb 04 and a Nasdaq minimum-bid deficiency notice on Feb 02, to an AI-focused strategic upgrade on Mar 13. Fiscal 2025 results on May 14 showed revenue growth but wider losses. On May 28, the company announced plans for the same ADS ratio change now being confirmed as effective on June 22, 2026, linking today’s update directly to that earlier structural move.
Key Terms
ads financial
reverse ads split financial
direct registration system financial
the depository trust company financial
depositary bank financial
cusip financial
deposit agreement financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
For the Company's ADS holders, the ADS Ratio Change will have the same effect as a one-for-eighteen reverse ADS split. There will be no change to the Company's Class A ordinary shares. On the Effective Date, holders of ADSs in the Direct Registration System and in The Depository Trust Company will have their ADSs automatically exchanged and need not take any action. The exchange of every eighteen (18) then-held existing ADSs for one (1) new ADS will occur automatically on the Effective Date, with the then-held ADSs being cancelled and new ADSs being issued by Citibank, N.A., the depositary bank for the Company's ADS program (the "Depositary").
The Company's ADSs are expected to begin trading on the Nasdaq Stock Market on a post-reverse ADS split basis under the same ticker symbol "POM" at the market opening on the Effective Date. The new CUSIP number for the Company's ADSs following the ADS Ratio Change will be 73181R207.
No fractional new ADSs will be issued in connection with the ADS Ratio Change. Instead, fractional entitlements to new ADSs will be aggregated and sold by the Depositary and the net cash proceeds from the sale of the fractional ADS entitlements will be distributed to the applicable ADS holders by the Depositary, in each case in accordance with the Depositary's then-current procedures and practices and after any deductions as provided in the deposit agreement between the Company and the Depositary for the ADSs.
As a result of the ADS Ratio Change, the ADS trading price is expected to increase proportionally, although the Company can give no assurance that the ADS trading price after the ADS Ratio Change will be equal to or greater than eighteen times the ADS trading price before the change.
About POMDOCTOR LIMITED
POMDOCTOR LIMITED is a leading online medical services platform for chronic diseases in China, ranking sixth on China's Internet hospital market based on the number of contracted doctors in 2022, according to Frost & Sullivan. Focusing on chronic disease management and pharmaceutical services, the Company offers a one-stop platform for medical services, organically connecting patients with doctors and pharmaceutical products. The Company's operations primarily include Internet hospital and pharmaceutical supply chain, connecting users, pharmacies, suppliers, medical professionals, and other healthcare participants. Through this model, POMDOCTOR aims to enhance the efficiency and transparency of the healthcare value chain. The Company's mission is to provide effective prevention and treatment solutions to alleviate patients' sufferings from illnesses. Its vision is to become the most trustworthy medical and healthcare services platform. For more information, please visit the Company's website: http://ir.7shiliu.com.
Forward-Looking Statements
Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company's current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can find many (but not all) of these statements by the use of words such as "approximates," "believes," "hopes," "expects," "anticipates," "estimates," "projects," "intends," "plans," "will," "would," "should," "could," "may" or other similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company's filings with the SEC.
For more information, please contact:
POMDOCTOR LIMITED
Investor Relations Department
Email: ir@7lk.com
Ascent Investor Relations LLC
Tina Xiao
Phone: +1-646-932-7242
Email: investors@ascent-ir.com
View original content:https://www.prnewswire.com/news-releases/pomdoctor-limited-announces-ads-ratio-change-to-be-effective-on-june-22-2026-302801244.html
SOURCE POMDOCTOR LIMITED